This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G. Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. Biomed Res Int. 2021; 2021:1738932. doi: 10.1155/2021/1738932. PMID: 34337000; PMCID: PMC8294963.GuoKXiaoWChenXZhaoZLinYChenGEpidemiological Trends of Head and Neck Cancer: A Population-Based Study20212021173893210.1155/2021/173893234337000PMC8294963Open DOISearch in Google Scholar
Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016; 91(3): 386–96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243.MarurSForastiereAAHead and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment20169133869610.1016/j.mayocp.2015.12.01726944243Open DOISearch in Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3): 209–49. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAGlobal Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries20217132094910.3322/caac.21660Epub 2021 Feb 4.33538338Open DOISearch in Google Scholar
Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK et al. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer. 2022; 21(1): 31–47. doi: 10.1186/s12943-022-01503-1. PMID: 35081970; PMCID: PMC8790852.RajSKesariKKKumarARathiBSharmaAGuptaPKMolecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer2022211314710.1186/s12943-022-01503-135081970PMC8790852Open DOISearch in Google Scholar
Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D et al. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw. 2022; 20(3): 224–34. doi: 10.6004/jnccn.2022.0016. PMID: 35276673.CaudellJJGillisonMLMaghamiESpencerSPfisterDGAdkinsDNCCN Guidelines® Insights: Head and Neck Cancers, Version 1.202220222032243410.6004/jnccn.2022.001635276673Open DOISearch in Google Scholar
Kaidar-Person O, Gil Z, Billan S. Precision medicine in head and neck cancer. Drug Resist Updat. 2018; 40:13–6. doi: 10.1016/j.drup.2018.09.001. Epub 2018 Sep 25. PMID: 30466712.Kaidar-PersonOGilZBillanSPrecision medicine in head and neck cancer20184013610.1016/j.drup.2018.09.001Epub 2018 Sep 25.30466712Open DOISearch in Google Scholar
Zhan C, Yang X, Song X, Yan L. Radiotherapy vs surgery for T1-2N0M0 laryngeal squamous cell carcinoma: A population-based and propensity score matching study. Cancer Med. 2018; 7(7): 2837–47. doi: 10.1002/cam4.1525. Epub 2018 May 7. PMID: 29733513; PMCID: PMC6051150.ZhanCYangXSongXYanLRadiotherapy vs surgery for T1-2N0M0 laryngeal squamous cell carcinoma: A population-based and propensity score matching study20187728374710.1002/cam4.1525Epub 2018 May 7.29733513PMC6051150Open DOISearch in Google Scholar
Hilal L, Moukarbel R, Ollaik F, Yang P, Youssef B. Patient Selection for Surgery vs Radiotherapy for Early Stage Oropharyngeal Cancer. Cancer Control. 2021;28:10732748211050770. doi: 10.1177/10732748211050770. PMID: 34936505; PMCID: PMC8704187.HilalLMoukarbelROllaikFYangPYoussefBPatient Selection for Surgery vs Radiotherapy for Early Stage Oropharyngeal Cancer20212810732748211050770.10.1177/1073274821105077034936505PMC8704187Open DOISearch in Google Scholar
Iqbal MS, Chaw C, Kovarik J, Aslam S, Jackson A, Kelly J et al. Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival. Int Arch Otorhinolaryngol. 2017; 21(2): 171–7. doi: 10.1055/s-0036-1594020. Epub 2016 Dec 19. PMID: 28382126; PMCID: PMC5375948.IqbalMSChawCKovarikJAslamSJacksonAKellyJPrimary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival2017212171710.1055/s-0036-1594020Epub 2016 Dec 19.28382126PMC5375948Open DOISearch in Google Scholar
Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1): 4–14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14. PMID: 19446902.PignonJPle MaîtreAMaillardEBourhisJMACH-NC Collaborative GroupMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients200992141410.1016/j.radonc.2009.04.014Epub 2009 May 14.19446902Open DOISearch in Google Scholar
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS et al; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156: 281–93. doi: 10.1016/j.radonc.2021.01.013. Epub 2021 Jan 27. PMID: 33515668; PMCID: PMC8386522.LacasBCarmelALandaisCWongSJLicitraLTobiasJSMACH-NC Collaborative GroupMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group20211562819310.1016/j.radonc.2021.01.013Epub 2021 Jan 27.33515668PMC8386522Open DOISearch in Google Scholar
Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE et al. Adverse Events Associated With Concurrent Chemoradiation Therapy in Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg. 2009;135(12):1209–17. doi:10.1001/archoto.2009.174GivensDJKarnellLHGuptaAKClamonGHPagedarNAChangKEAdverse Events Associated With Concurrent Chemoradiation Therapy in Patients With Head and Neck Cancer20091351212091710.1001/archoto.2009.174Open DOISearch in Google Scholar
Li Y, Jiang Y, Qiu B, Sun H, Wang J. Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review. J Transl Med. 2022 Dec 6;20(1):566. doi: 10.1186/s12967-022-03774-0. PMID: 36474246; PMCID: PMC9724430.LiYJiangYQiuBSunHWangJCurrent radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review2022Dec620156610.1186/s12967-022-03774-036474246PMC9724430Open DOISearch in Google Scholar
Borsetto D, Polesel J, Tirelli G, Menegaldo A, Baggio V, Gava A et al. Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. Laryngoscope. 2021; 131(3):E836–45. doi: 10.1002/lary.28882. Epub 2020 Jun 26. PMID: 32589769.BorsettoDPoleselJTirelliGMenegaldoABaggioVGavaAPretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer20211313E8364510.1002/lary.28882Epub 2020 Jun 26.32589769Open DOISearch in Google Scholar
Wang S, Feng Y, Xie Y, Zhao X, Ma J, Liu X et al. High fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection. Eur Arch Otorhinolaryngol. 2022; 279(9): 4541–8. doi: 10.1007/s00405-022-07391-x. Epub 2022 Apr 24. PMID: 35462579.WangSFengYXieYZhaoXMaJLiuXHigh fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection202227994541810.1007/s00405-022-07391-xEpub 2022 Apr 24.35462579Open DOISearch in Google Scholar
Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020; 18(1): 360. doi: 10.1186/s12916-020-01817-1. PMID: 33213430; PMCID: PMC7678319.CuppMACariolouMTzoulakiIAuneDEvangelouEBerlanga-TaylorAJNeutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies202018136010.1186/s12916-020-01817-133213430PMC7678319Open DOISearch in Google Scholar
Mazaki J, Katsumata K, Kasahara K, Tago T, Wada T, Kuwabara H et al. Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis. BMC Cancer. 2020; 20(1): 922. doi: 10.1186/s12885-020-07429-5. PMID: 32977767; PMCID: PMC7519490.MazakiJKatsumataKKasaharaKTagoTWadaTKuwabaraHNeutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis202020192210.1186/s12885-020-07429-532977767PMC7519490Open DOISearch in Google Scholar
Pirozzolo G, Gisbertz SS, Castoro C, van Berge Henegouwen MI, Scarpa M. Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis. 2019;11(7):3136–45. doi: 10.21037/jtd.2019.07.30. PMID: 31463142; PMCID: PMC6688029.PirozzoloGGisbertzSSCastoroCvan Berge HenegouwenMIScarpaMNeutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis201911731364510.21037/jtd.2019.07.3031463142PMC6688029Open DOISearch in Google Scholar
Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017; 19(1): 2. doi: 10.1186/s13058-016-0794-1. PMID: 28057046; PMCID: PMC5217326.EthierJLDesautelsDTempletonAShahPSAmirEPrognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis2017191210.1186/s13058-016-0794-128057046PMC5217326Open DOISearch in Google Scholar
Magdy M, Hussein T, Ezzat A, Gaballah A. Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer. J Gastrointest Cancer. 2019; 50(4): 763–8. doi: 10.1007/s12029-018-0144-x. PMID: 30058031.MagdyMHusseinTEzzatAGaballahAPre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer2019504763810.1007/s12029-018-0144-x30058031Open DOISearch in Google Scholar
Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T. Neutrophil-to-lymphocyte ratio in head and neck cancer. J Med Imaging Radiat Oncol. 2015; 59(4): 514–9. doi: 10.1111/1754-9485.12305. Epub 2015 Apr 23. PMID: 25908427.HaddadCRGuoLClarkeSGuminskiABackMEadeTNeutrophil-to-lymphocyte ratio in head and neck cancer2015594514910.1111/1754-9485.12305Epub 2015 Apr 23.25908427Open DOISearch in Google Scholar
Rachidi S, Wallace K, Wrangle JM, Day TA, Alberg AJ, Li Z. Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. 2016; 38(Suppl 1): E1068–74. doi: 10.1002/hed.24159. Epub 2015 Sep 28. PMID: 26040762; PMCID: PMC4909151.RachidiSWallaceKWrangleJMDayTAAlbergAJLiZNeutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma201638Suppl 1E10687410.1002/hed.24159Epub 2015 Sep 28.26040762PMC4909151Open DOISearch in Google Scholar
Malik A, Mishra A, Mair M, Chakrabarti S, Garg A, Singhvi H et al. Role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in oral cavity cancers. Indian J Med Paediatr Oncol. 2019; 40(1): 94–100.MalikAMishraAMairMChakrabartiSGargASinghviHRole of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in oral cavity cancers201940194100Search in Google Scholar
Das SM, Singh D, Bose A, Das S, Neena Prasad S, Dastidar AG. Role of systemic inflammatory markers (biomarkers) as important prognostic factors for survival in head and neck cancer. Biomedicine. 2021; 41(4): 837–44. doi: 10.51248/.v41i4.1363DasSMSinghDBoseADasSNeena PrasadSDastidarAGRole of systemic inflammatory markers (biomarkers) as important prognostic factors for survival in head and neck cancer20214148374410.51248/.v41i4.1363Open DOISearch in Google Scholar
Tazzyman S, Niaz H, Murdoch C. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol. 2013; 23(3): 149–58. doi: 10.1016/j.semcancer.2013.02.003. Epub 2013 Feb 11. PMID: 23410638.TazzymanSNiazHMurdochCNeutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth20132331495810.1016/j.semcancer.2013.02.003Epub 2013 Feb 11.23410638Open DOISearch in Google Scholar
Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017; 16(1):137–43. doi: 10.1186/s12943-017-0707-7. PMID: 28810877; PMCID: PMC5558711.OcanaANieto-JiménezCPandiellaATempletonAJNeutrophils in cancer: prognostic role and therapeutic strategies20171611374310.1186/s12943-017-0707-728810877PMC5558711Open DOISearch in Google Scholar
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007; 117(5): 1137–46. doi: 10.1172/JCI31405. PMID: 17476343; PMCID: PMC1857231.SwannJBSmythMJImmune surveillance of tumors2007117511374610.1172/JCI3140517476343PMC1857231Open DOISearch in Google Scholar
Wang X, Zhao Z, Wang P, Geng X, Zhu L, Li M. Low Lymphocyte Count is Associated with Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients. Front Oncol. 2020; 10: 997. doi: 10.3389/fonc.2020.00997. PMID: 32656085; PMCID: PMC7324641.WangXZhaoZWangPGengXZhuLLiMLow Lymphocyte Count is Associated with Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients20201099710.3389/fonc.2020.0099732656085PMC7324641Open DOISearch in Google Scholar
Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019; 9: 19673. https://doi.org/10.1038/s41598-019-56218-zHowardRKanetskyPAEganKMExploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer2019919673https://doi.org/10.1038/s41598-019-56218-zSearch in Google Scholar
Tu XP, Qiu QH, Chen LS, Luo XN, Lu ZM, Zhang SY et al. Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma. BMC Cancer. 2015; 15(1):743–50. doi: 10.1186/s12885-015-1727-6. PMID: 26482899; PMCID: PMC4615885.TuXPQiuQHChenLSLuoXNLuZMZhangSYPreoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma20151517435010.1186/s12885-015-1727-626482899PMC4615885Open DOISearch in Google Scholar
Zeng YC, Chi F, Xing R, Xue M, Wu LN, Tang MY et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol. 2016;46(2):126–31. doi: 10.1093/jjco/hyv175. Epub 2015 Nov 25. PMID: 26611205; PMCID: PMC5007580.ZengYCChiFXingRXueMWuLNTangMYPre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy20164621263110.1093/jjco/hyv175Epub 2015 Nov 25.26611205PMC5007580Open DOISearch in Google Scholar
Zhang B, Du W, Gan K, Fang Q, Zhang X. Significance of the neutrophil-to-lymphocyte ratio in young patients with oral squamous cell carcinoma. Cancer Manag Res. 2019; 11:7597–603. doi: 10.2147/CMAR.S211847. PMID: 31496814; PMCID: PMC6691951.ZhangBDuWGanKFangQZhangXSignificance of the neutrophil-to-lymphocyte ratio in young patients with oral squamous cell carcinoma201911759760310.2147/CMAR.S21184731496814PMC6691951Open DOISearch in Google Scholar
Takenaka Y, Kitamura T, Oya R, Ashida N, Shimizu K, Takemura K et al. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis. PLoS One. 2017; 12(7):e0181478. doi: 10.1371/journal.pone.0181478. PMID: 28715474; PMCID: PMC5513538.TakenakaYKitamuraTOyaRAshidaNShimizuKTakemuraKPrognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis2017127e018147810.1371/journal.pone.018147828715474PMC5513538Open DOISearch in Google Scholar
Yu Y, Wang H, Yan A, Wang H, Li X, Liu J et al. Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis. BMC Cancer. 2018; 18(1):1–9. https://doi.org/10.1186/s12885-018-4230-zYuYWangHYanAWangHLiXLiuJPretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis201818119https://doi.org/10.1186/s12885-018-4230-zSearch in Google Scholar
Cho Y, Kim JW, Yoon HI, Lee CG, Keum KC, Lee IJ. The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy. J Clin Med. 2018; 7(12):512–25. doi: 10.3390/jcm7120512. PMID: 30513928; PMCID: PMC6306798.ChoYKimJWYoonHILeeCGKeumKCLeeIJThe Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy20187125122510.3390/jcm712051230513928PMC6306798Open DOISearch in Google Scholar
Hashemi-Bahremani M, Mortazavi N, Novin K, Ameri A, Razzaghi Z. Blood neutrophil-to-lymphocyte ratio as a predictor of response to chemotherapy in head-and-neck cancers. J Head Neck Physicians Surg. 2019;7(1):20–5.Hashemi-BahremaniMMortazaviNNovinKAmeriARazzaghiZBlood neutrophil-to-lymphocyte ratio as a predictor of response to chemotherapy in head-and-neck cancers201971205Search in Google Scholar
Gorphe P, Bouhir S, Garcia GCTE, Alali A, Even C, Breuskin I et al. Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy. Laryngoscope. 2020 Apr;130(4):E144–50. doi: 10.1002/lary.28021. Epub 2019 Apr 22. PMID: 31006874.GorphePBouhirSGarciaGCTEAlaliAEvenCBreuskinIAnemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy2020Apr1304E1445010.1002/lary.28021Epub 2019 Apr 22.31006874Open DOISearch in Google Scholar